English | Español

Horizon Therapeutics
Patient Daily | May 7, 2023

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
Patient Daily | Apr 24, 2023

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

Trending
+ Community
Patient Daily | Apr 17, 2025

ENT Practice Expert: OTO Forum 2025 will feature 'at least four topics that stand out as vital for doctors'
+ Pharmaceuticals
Patient Daily | Apr 17, 2025

UCSF neurosurgeon: 'The idea that 340B is about helping the poor is a fiction'
+ Pharmaceuticals
Patient Daily | Apr 23, 2025

Empower Pharmacy CEO on pharmaceutical industry pricing disparities: 'Is it fair to charge one person in another country 10 times more?'
+ Pharmaceuticals
Patient Daily | Apr 17, 2025

AI tool decodes cerebellar signals to improve understanding of brain disorders